TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02085083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone and email correspondence with an Inflammatory Bowel Disease Nurse
Description: The IBD pediatric-adult transition nurse will send an email each month containing:~Brief Questionnaire: A link to a secured website will be provided where participants will respond to a questionnaire.~Direct Nurse Contact: Telephone and email correspondence with an Inflammatory Bowel Disease Nurse~Educational module: Every other month, we will include in the email another link to an optional educational module that will be part of a curriculum to facilitate transition readiness.~MyHealth Passport~Study Questionnaire: A personalized link to a more comprehensive study questionnaire similar to the baseline questionnaire will be emailed in the 6th and 12th (final) email.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Intervention Arm
Description: Patients randomized to the control group will have receive email based questionnaires and information relating to the MyHealth Passport application. This intervention is not expected to significantly improve outcomes.
Study: NCT04157491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib and anti PD-1 antibody
Description: Anti-PD-1 antibody administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus Anlotinib 12 mg administered orally (PO) once daily (QD) Day1-Day14 during each 21-day cycle.
Study: NCT01786525

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: House Calls
Description: 60-minute home based educational intervention which will be administered by a health educator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: House Calls
Description: 60-minute home based educational intervention which will be administered by a health educator
Study: NCT04293562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT03396185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Patients who have EGFR-mutant stage IIIA-IIIB and unresectable lung adenocarcinoma will receive Icotinib with a dose of 125 mg three times per day orally till progressive disease or unaccepted toxicity as consolidation therapy after synchronous or sequential chemoradiotherapy.
Study: NCT02791997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Description: Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.
Study: NCT04293562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT
Study: NCT02791997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Description: Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Description: Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurophysiological tests
Description: Neurophysiological tests consist in the recording of EEG and/or MEG signals while realizing the neuropsychological tests, as well as MRI scanning to characterize the patients' brain lesions and reconstruct the brain sources of surface EEG/MEG signals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurophysiological tests
Description: Neurophysiological tests consist in the recording of EEG and/or MEG signals while realizing the neuropsychological tests, as well as MRI scanning to characterize the patients' brain lesions and reconstruct the brain sources of surface EEG/MEG signals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurophysiological tests
Description: Neurophysiological tests consist in the recording of EEG and/or MEG signals while realizing the neuropsychological tests, as well as MRI scanning to characterize the patients' brain lesions and reconstruct the brain sources of surface EEG/MEG signals.
Study: NCT01786525

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-Based Patient-Centered Decision Support Intervention
Description: Patients will be provided with access to the study website which will allow them to learn and receive LDKT support in a way the best meets their personal values and preferences
Study: NCT04293562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT
Study: NCT00791856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testosterone
Description: 28 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
Study: NCT04293562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study: NCT03997916

Intervention type: DEVICE
Group type: OTHER
Intervention: Belun Ring
Description: All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PSG
Description: All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
Study: NCT04293562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study: NCT02858882

Intervention type: OTHER
Intervention: Screening
Description: Screening of elite swimmers
Study: NCT04562844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sociale cognition
Description: several social cognition test
Study: NCT04293562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET
Study: NCT03281694

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: placebo skin patch and placebo oral solution

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine
Description: nicotine skin patch (7 mg/24 hrs) and placebo oral solution
Study: NCT04293562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET
Study: NCT03281694

Intervention type: DRUG
Group type: OTHER
Intervention: AVL-3288
Description: placebo skin patch and AVL-3288 oral solution (3 mg)

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine + AVL-3288
Description: nicotine skin patch (7 mg/24 hrs) and AVL-3288 oral solution (3 mg)
Study: NCT04293562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV
Study: NCT03334396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.
Study: NCT03151655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MATTeRS Video
Description: Narrative-based video intervention and accompanying workbook
Study: NCT03334396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.
Study: NCT00791856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone
Description: 14 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
Study: NCT03334396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study: NCT03151655

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Didactic Video
Description: Education only video
Study: NCT00648011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
Description: 20/25mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Accuretic™ Tablets 20 mg/25 mg
Description: 20/25mg, single dose fed
Study: NCT03334396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT03897647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: General Electric (GE) VScan
Description: This is a small, point-of-care, hand-held device used for ultrasound (POCUS). It uses sound waves to generate images without using any radiation.
Study: NCT03264820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Doppler
Description: - Laser measurements at the level of each finger at 47 °C and at ambient temperature

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Doppler
Description: - Laser measurements at the level of each finger at 47 °C and at ambient temperature

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser speckle
Description: - Laser measurements at the forearm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser speckle
Description: - Laser measurements at the forearm

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pain evaluation
Description: Visual scale assesment pain

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pain evaluation
Description: Visual scale assesment pain
Study: NCT04293562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV
Study: NCT03264820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood pressure and heart rate
Description: Measurement of blood pressure and heart rate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood pressure and heart rate
Description: Measurement of blood pressure and heart rate
Study: NCT01188265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 60 mg per day
Description: VPA plus dextromethorphan 60 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: VPA plus placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg
Description: VPA \& Dextromethorphan 30 mg per day
Study: NCT03936049

Intervention type: DRUG
Intervention: Liraglutide
Description: Liraglutide dispensing claim is used as the exposure group

Intervention type: DRUG
Intervention: DPP-4 inhibitor
Description: DPP-4 inhibitor dispensing claim is used as the reference group
Study: NCT00493246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen
Study: NCT04223999

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skullremodeling surgery
Description: Strategically placed cranial burrholes in order to improve the TTField dose focally in the tumor.
Study: NCT04293562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib Fumarate
Description: Given PO/NG/G-tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib Fumarate
Description: Given PO/NG/G-tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib Fumarate
Description: Given PO/NG/G-tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib Fumarate
Description: Given PO/NG/G-tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib Fumarate
Description: Given PO/NG/G-tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib Fumarate
Description: Given PO/NG/G-tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib Fumarate
Description: Given PO/NG/G-tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib Fumarate
Description: Given PO/NG/G-tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT01560416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganetespib